Menu
Menu
Menu
Menu
Although the Kenyan government has made efforts to invest in maternal health over the past 15 years, there is no evidence of decline in maternal mortality. To provide necessary evidence to inform maternal health care provision, we conducted a nationally representative study to describe the incidence and causes of maternal near-miss (MNM), and the quality of obstetric care in referral hospitals in Kenya. We collected data from 54 referral hospitals in 27 counties. Individuals admitted with potentially life-threatening conditions (using World Health Organization criteria) in pregnancy, childbirth or puerperium over a three month study period were eligible for inclusion in our study. All cases of severe maternal outcome (SMO, MNM cases and deaths) were prospectively identified, and after consent, included in the study. The national annual incidence of MNM was 7.2 per 1,000 live births and the intra-hospital maternal mortality ratio was 36.2 per 100,000 live births. The major causes of SMOs were postpartum haemorrhage and severe pre-eclampsia/eclampsia. However, only 77% of women with severe preeclampsia/eclampsia received magnesium sulphate and 67% with antepartum haemorrhage who needed blood received it. To reduce the burden of SMOs in Kenya, there is need for timely management of complications and improved access to essential emergency obstetric care interventions.
We conducted a cross-sectional study within a nationally representative sample of public and private referral-level facilities in Kenya sub-county, county and national hospitals within a three-month period between February and May 2018. This period followed an extended national health workers strike by doctors and then nurses in Kenya which ended in November 2017, and some facilities started later than others due to administrative bottlenecks13. All county (n = 16) and national (n = 2) hospitals were eligible for participation. We generated a simple random sample, stratified by region, of all sub-county hospitals (n = 424) and 46 were selected to participate. Selected facilities that declined to participate, or that were non-functional at the time of the survey were replaced with similar-level facilities drawn from a replacement list generated before the study commenced. Fifty-four facilities participated in the study, with a response rate of 86% (Supplementary Table S1 shows the sampling and response rates for facilities and patients). All patients of reproductive age admitted with a potentially life-threatening condition (PLTC), or as an MNM, or an MD that occurred in the facility during pregnancy, delivery or within 42 days of delivery or termination of pregnancy were eligible for inclusion. PLTCs are defined as “an extensive category of clinical conditions, including diseases that can threaten a woman’s life during pregnancy and labour and after termination of pregnancy3.” PLTCS may recover from their conditions with clinical management or progress to become MNMs, which may similarly recover with clinical care or result in MDs. MD was defined according to the International Classification of Disease (ICD-10)14. Severe maternal outcomes (SMO) included all MNMs and MDs. Informed consent was sought from eligible patients when they were treated and in a clinically stable condition before discharge. Trained study clinicians extracted individual-level data from patient files for patients who consented to participate in the study. One patient who experienced a MNM event did not consent to participate in the study (0.3%) and we were unable to obtain consent for participation for seven patients who died (29%) (data not shown). We used two methods for defining MNM criteria: the WHO operational definitions, based on organ failure, and an adaptation of these operational definitions for the Kenyan context (see Supplementary Table S3 for comparison). We included the Kenyan adapted criteria as evidence from other studies on MNM in low- and middle-income countries (LMICs) suggests that the original WHO criteria (particularly the management and laboratory-based criteria) often has limited applicability in such contexts8. We however retained all the original WHO criteria in our instrument to allow for comparisons with studies from other contexts. Questions for the Kenyan adaptation were added to questions from the published WHO MNM surveillance and assessment tool, which we used to develop our data collection tool3. These adaptations were selected based on previous studies attempting to validate the criteria of the WHO near-miss approach in other LMICs and with input from the clinicians participating in the study15,16. All MNM indicators were defined according to the WHO near-miss manual3. For some conditions within the WHO MNM organ dysfunction categories (shock, abnormal liver enzymes, and massive blood transfusion), we collected detailed information on the clinical signs and symptoms used to diagnose each condition. Each participating facility identified one study clinician, such as a medical doctor, clinical officer or nurse, who was trained to conduct face-to-face interviews and extract data from medical records. The national hospitals and county hospitals with expected higher caseloads had two to three interviewers. All facility interviewers participated in a two-day training on the study procedures, and piloted the tool in a sub-county hospital in Nairobi. The facility interviewers visited the obstetrics wards, delivery rooms, emergency rooms and intensive care units daily to identify eligible patients. Each eligible patient admitted (except MDs) was first approached by their health care provider who informed them about the study and asked if the study team could speak with them. If they agreed to speak to the study team and was in a stable condition, the facility interviewer further explained the study and obtained their written consent to participate. Consent included permission to interview them, their health care provider and to review their medical records. Upon receiving each informed consent to participate in the study, the study clinicians interviewed the patient’s health care provider, reviewed their health records to extract information about their clinical condition using the study tool, and interviewed them to collect any information not recorded in their health records. We also extracted individual level data for patients who came in with a complication, died and had consented to participate in the study before they died. Patients who did not consent (either because they did not give consent or could not provide consent before they died), and those who were dead on admission were recorded in the monthly caseloads and included in the intra-hospital MMR and mortality index, but their individual data was not analysed. The study team provided regular oversight of the study process to assess quality and completeness of data collection. To minimize the number of missed cases, we created a daily log for the study clinicians to track all patients perceived to have serious conditions across the relevant wards in each facility. Thereafter, the study clinicians reviewed the medical records of each tracked case to determine if the patient was admitted with or developed any PLTCs that would make them eligible for the study. We also produced a visual guide of PLTCs to remind interviewers how to determine study eligibility. Before data entry, a medical doctor performed validity crosschecks of questionnaires for clinical inconsistencies or missing data. Double data entry was done for 10% of data collection forms and inconsistency checks programmed in the statistical software to flag any potential errors. If errors were found, the study team followed up with the facility interviewers to verify or obtain the correct information from the patient’s medical records related to these discrepancies. We used a structured data collection form to obtain the total number of deliveries, live births, gynaecological admissions, post-abortion care admissions, and MDs occurring during each month of the study period from each facility’s Health Management Information System (HMIS). We conducted descriptive analyses of study participants characteristics, underlying and contributory causes of severe morbidity, and the distribution of organ dysfunction, by type of SMO. National estimates of MNM were generated using the adapted Kenyan definition. The number of MNM cases was annualized from the three-month study period and weighted for study design to obtain a national annual incidence of MNM for 2018. We estimated the SMO ratio (SMOR), intra-hospital MMR, MNM ratio (MNMR), and other MNM indicators at the national and regional levels. We also described the corresponding standards of care for each complication to assess the quality of care provided using the WHO MNM guidelines. We compared the number of MNM generated for each organ dysfunction category and their criteria using our adapted criteria and the WHO criteria. We also examined if the WHO approach of asking clinicians to select checkboxes to indicate a diagnosis of some MNM conditions aligned with the clinical definitions WHO provided for these conditions. To do this, we compared the selection of diagnoses using just the checkbox to a diagnosis generated in statistical software using the constellation of clinical signs and symptoms WHO requires to detect the condition diagnosed. Data analysis was conducted using Stata Version 15.117.
